TY - JOUR
T1 - Fibrinolytic activity after administration of diflunisal and aspirin
T2 - A double-blind, randomized, placebo-controlled clinical trial
AU - Green, David
AU - Davies, Richard O.
AU - Holmes, Geoffrey I.
AU - Johnson, Cynthia
AU - Kohl, Helga
AU - Reynolds, Nancy
AU - Ts'ao, Chung hsin
PY - 1983/1/1
Y1 - 1983/1/1
N2 - A double-blind, randomized, placebo-controlled clinical trial was conducted to determine whether fibrinolysis was increased by the chronic administration of aspirin or diflunisal. Healthy male and female volunteers were randomized to receive either aspirin (1,300 mg every 12 h; 10 subjects), diflunisal (1,000 mg initially, then 500 mg every 12 h; 10 subjects), or placebo (10 subjects) for 8 days. Fibrinolytic activity was examined with the clot lysis assay, using native whole blood, platelet-rich plasma, and platelet-poor plasma, and with the kaolin-activated euglobulin lysis test. In addition, measurements were made of fibrinogen, fibrin/fibrinogen degradation products, plasminogen, and the thrombin time. Clot lysis was greater in whole blood and platelet-rich plasma than in platelet-poor plasma, and increased lysis was observed in specimens obtained in the afternoon as compared to those obtained in the morning. Fibrinolytic activity in the afternoon samples was significantly enhanced by both aspirin and diflunisal at the start of the trial (p < 0.05), but by the afternoon of day 8, only aspirin showed some enhancement. Fibrinolytic activity, as measured by the euglobulin lysis time, actually declined in all study groups during the course of drug administration. No significant changes were recorded in any of the other assayed hemostatic parameters. We conclude that aspirin and diflunisal exert a modest, nonsustained enhancing effect on fibrinolysis in normal subjects.
AB - A double-blind, randomized, placebo-controlled clinical trial was conducted to determine whether fibrinolysis was increased by the chronic administration of aspirin or diflunisal. Healthy male and female volunteers were randomized to receive either aspirin (1,300 mg every 12 h; 10 subjects), diflunisal (1,000 mg initially, then 500 mg every 12 h; 10 subjects), or placebo (10 subjects) for 8 days. Fibrinolytic activity was examined with the clot lysis assay, using native whole blood, platelet-rich plasma, and platelet-poor plasma, and with the kaolin-activated euglobulin lysis test. In addition, measurements were made of fibrinogen, fibrin/fibrinogen degradation products, plasminogen, and the thrombin time. Clot lysis was greater in whole blood and platelet-rich plasma than in platelet-poor plasma, and increased lysis was observed in specimens obtained in the afternoon as compared to those obtained in the morning. Fibrinolytic activity in the afternoon samples was significantly enhanced by both aspirin and diflunisal at the start of the trial (p < 0.05), but by the afternoon of day 8, only aspirin showed some enhancement. Fibrinolytic activity, as measured by the euglobulin lysis time, actually declined in all study groups during the course of drug administration. No significant changes were recorded in any of the other assayed hemostatic parameters. We conclude that aspirin and diflunisal exert a modest, nonsustained enhancing effect on fibrinolysis in normal subjects.
KW - Aspirin
KW - Clot lysis
KW - Diflunisal
KW - Fibrinolysis
UR - http://www.scopus.com/inward/record.url?scp=0021015632&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0021015632&partnerID=8YFLogxK
U2 - 10.1159/000214828
DO - 10.1159/000214828
M3 - Article
C2 - 6365701
AN - SCOPUS:0021015632
SN - 1424-8832
VL - 13
SP - 394
EP - 398
JO - Pathophysiology of Haemostasis and Thrombosis
JF - Pathophysiology of Haemostasis and Thrombosis
IS - 6
ER -